Cancer Res Treat.  2023 Apr;55(2):385-399. 10.4143/crt.2023.447.

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2020

• Kang MJ
• Jung KW
• Bang SH
• Choi SH
• Park EH
• Yun EH
• Kim HJ
• Kong HJ
• Im JS
• Seo HG
• The Community of Population-Based Regional Cancer Registries*

• KMID: 2541226
• DOI: http://doi.org/10.4143/crt.2023.447

Abstract

Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2020.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2020, with survival follow-up until December 31, 2021. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
The number of new cancer diagnoses in 2020 decreased by 9,218 cases (3.6%) compared to 2019. In 2020, newly diagnosed cancer cases and deaths from cancer were reported as 247,952 (age-standardized rate [ASR], 262.2 per 100,000) and 82,204 (ASR, 69.9 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.0% annually from 2012 to 2015, thereafter, followed by nonsignificant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years. The 5-year relative survival between 2016 and 2020 was 71.5%, which contributed to prevalent cases reaching over 2.2 million in 2020.
Conclusion
In 2020, the number of newly diagnosed cancer patients decreased due to the coronavirus disease 2019 pandemic, but the overall trend is on the rise. Cancer survival rates have improved over the past decades. As the number of cancer survivors increases, a comprehensive cancer control strategy should be implemented in line with the changing aspects of cancer statistics. The long-term impact of the coronavirus disease 2019 pandemic on cancer statistics needs to be investigated in the future.

Keyword

Neoplasms; Incidence; Mortality; Survival; Prevalence; Korea

Figure

• 

  Fig. 1 The five common sites of cancer incidence by age group and sex in Korea, 2020. (A) Men. (B) Women. Numbers in the graph are age-specific incidence rates per 100,000. CNS, central nervous system.

• 

  Fig. 2 Age-specific incidence rates of common cancers for 2020 in Korea. (A) Men. (B) Women.

• 

  Fig. 3 Annual age-standardized cancer incidence and death rates by sex for all sites from 1983 to 2020 in Korea. Age standardization was based on the Segi’s world standard population.

• 

  Fig. 4 Trends in age-standardized incidences of selected cancers by sex from 1999 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on Segi’s world standard population.

• 

  Fig. 5 Trends in age-standardized mortalities of selected cancers by sex from 1983 to 2020 in Korea. (A) Men. (B) Women. Age standardization was based on the Segi’s world standard population.

• 

  Fig. 6 Five-year relative survival rates by stage at diagnosis and stage distribution of selected cancers by sex in Korea, 2016–2020. (A) Men. (B) Women. Staging according to the Surveillance, Epidemiology, and End Results (SEER) stage categories. For each cancer type, stage categories do not total 100% because sufficient information was not available to stage all cases. a)Includes the gallbladder and other/unspecified parts of the biliary tract.

• 

  Fig. 7 Prevalent cases of common cancers by time since cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2021 among all cancer patients diagnosed between 1999 and 2020.

Reference

References

1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2023 Feb 6]. Available from: https://gco.iarc.fr/today.

2. Statistics Korea [Internet]. Daejeon: Statistics Korea;2021. [cited 2023 Feb 6]. Available from: http://kosis.kr.

3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33.

4. Lee K, Lee YY, Suh M, Jun JK, Park B, Kim Y, et al. Impact of COVID-19 on cancer screening in South Korea. Sci Rep. 2022; 12:11380.

5. Teglia F, Angelini M, Astolfi L, Casolari G, Boffetta P. Global association of COVID-19 pandemic measures with cancer screening: a systematic review and meta-analysis. JAMA Oncol. 2022; 8:1287–93.

6. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.

7. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998; 45:1011–7.

8. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. 1st rev. Geneva: World Health Organization;2013.

9. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. . Geneva: World Health Organization;1994.

10. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, et al. Global cancer observatory: cancer today – data and methods [Internet]. Lyon: International Agency for Research on Cancer;2020. [cited 2023 Feb 6]. Available from: https://gco.iarc.fr/today/data-sources-methods.

11. Cancer incidence in five continents, XI Chapter 3. Classification and coding [Internet]. Lyon: International Agency for Research on Cancer;2017. [cited 2023 Feb 6]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter3.aspx.

12. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual 2000: codes and coding instructions. National Cancer Institute, NIH Pub No. 01-4969. Bethesda, MD: National Cancer Institute;2001.

13. Cancer incidence in five continents, XI Chapter 7. Age standardization [Internet]. Lyon: International Agency for Research on Cancer;2017. [cited 2023 Feb 6]. Available from: http://ci5.iarc.fr/CI5-XI/Pages/Chapter7.aspx.

14. Segi M. Cancer mortality for selected sites in 24 countries 1950–1957. Sendai: Tohoku University School of Medicine;1960.

15. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note, No 10. Bethesda, MD: National Cancer Institute;1959.

16. Paul Dickman [Internet]. Stockholm: PaulDickman.com;2016. [cited 2023 Feb 6]. Available from: http://www.pauldickman.com.